Arvinas

📍 New Haven, United States🗓 Founded 2013👥 306 employees💰 Last funded Mar 2018
Biotechnology Research🌐 arvinas.com
Website LinkedIn
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2013
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Switzerland
1
United States
1
Frequently asked questions
Who invested in Arvinas?
Arvinas has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Arvinas last raise funding?
The most recent investment in Arvinas recorded on gritt.io was in March 2018.
When was Arvinas founded?
Arvinas was founded in 2013.
What industry is Arvinas in?
Arvinas operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Arvinas based?
Arvinas is headquartered in New Haven, United States.